Collplant Holdings (CLGN) AI Stock Analysis

• Market Cap: $20.47M
• Dividend Yield: N/A
• Average Volume (3M): 29.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: 280.77%
• EPS Growth: 32.82%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 12,716,014
• 10 Day Avg. Volume: 15,198
• 30 Day Avg. Volume: 29,183
• PEG Ratio: -0.02
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 80.07
• P/FCF Ratio: -2.83
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: 1.49
• Enterprise Value/Gross Profit: 5.91
• Enterprise Value/Ebitda: -0.33
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $2.00 ▲(32.45% Upside)

The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield.

Positive Factors

Margin Improvement

A sustained positive gross margin (~25%) after a prior negative period suggests improving unit economics and product-market fit for core collagen products. Durable margin recovery supports scale-up, reduces incremental cash burn per sale, and strengthens the pathway to longer-term profitability.

Strategic Partnerships & Distribution

North American logistics expansion and clinical collaborations (e.g., Mayo Clinic) provide validation, improve market access, and create scalable commercial channels. These structural partnerships enhance adoption, diversify revenue streams, and raise competitive barriers over the medium term.

Manageable Financial Leverage

Relatively low reported leverage (debt-to-equity ~0.32) preserves financial flexibility while the company scales. Manageable debt reduces insolvency risk, supports continued R&D and commercialization investment, and buys runway to execute strategic initiatives without immediate distress.

Negative Factors

Persistent Cash Burn

Sustained negative operating and free cash flow (~-$10M TTM) indicates the business consumes cash to fund operations. Over a multi-month horizon this raises material funding risk, forces recurrent capital raises, constrains strategic investments, and increases the likelihood of shareholder dilution.

Large Ongoing Losses

Extremely negative net margins (~-491%) reflect costs far outpacing revenues despite recent top-line recovery. Persisting large losses signal the business has not yet achieved scalable profitability, heightening execution risk and reliance on external financing to sustain growth initiatives.

Shrinking Equity Base

A sharp reduction in shareholder equity over recent years erodes the balance-sheet buffer and indicates cumulative losses or dilution. This structural decline increases dependence on future capital raises, raises dilution risk for shareholders, and weakens the firm's ability to absorb setbacks long-term.

Collplant Holdings Business Overview & Revenue Model

Company Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

How the Company Makes Money

CollPlant generates revenue through the commercialization of its proprietary collagen products and technologies. The company's primary revenue streams include direct sales of its wound healing and tissue regeneration products to hospitals, clinics, and healthcare providers, as well as licensing agreements with strategic partners in the medical and aesthetic industries. Significant partnerships with key players in the biotechnology and medical device sectors enhance its market reach and facilitate product development. Additionally, CollPlant may receive milestone payments and royalties from its partners based on the commercial success of collaborative products, further contributing to its earnings.

Collplant Holdings Financial Statement Overview

Summary

Revenue and gross margin improved in the TTM period, but the core financial picture remains weak with very large operating/net losses (net margin near -491%) and persistent cash burn (about -$10M operating and free cash flow). Balance sheet leverage is manageable, yet equity has shrunk substantially over time, raising ongoing funding/dilution risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply versus 2024, and gross margin turned positive (~25%) after a deeply negative 2024. However, profitability remains very weak: the company is still generating large operating losses and a sizeable net loss in TTM, with net margin near -491%, indicating costs remain far out of line with the current revenue base. Results have also been highly volatile year-to-year (strong 2021/2023 revenue levels followed by a collapse in 2024), which increases execution risk.

Balance Sheet

Leverage looks manageable with debt around $2.9M against equity of ~$9.3M in TTM (debt-to-equity ~0.32), an improvement versus the high leverage seen in 2020. That said, equity has declined substantially over time (from ~45M in 2021 to ~9M in TTM), and returns to shareholders are strongly negative in recent periods, reflecting ongoing losses and potential future dilution/financing needs if cash burn continues.

Cash Flow

Cash generation is a key weakness: TTM operating cash flow is about -$10.0M and free cash flow about -$10.0M, indicating the business is consuming cash rather than funding itself. While cash burn improved versus 2024 (less negative operating and free cash flow), free cash flow growth remains negative and the company’s cash spending pattern has been persistently negative in most years, heightening funding risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.48M	515.00K	10.96M	299.00K	15.64M	6.14M
Gross Profit	622.00K	-2.15M	7.87M	-1.18M	13.64M	2.68M
EBITDA	-11.05M	-15.55M	-5.91M	-15.81M	1.05M	-5.08M
Net Income	-12.16M	-16.61M	-7.02M	-16.93M	237.00K	-5.77M
Balance Sheet
Total Assets	14.09M	18.71M	34.13M	37.77M	51.22M	10.84M
Cash, Cash Equivalents and Short-Term Investments	8.55M	11.91M	26.67M	29.65M	43.30M	3.33M
Total Debt	2.94M	3.08M	3.16M	2.91M	3.61M	3.39M
Total Liabilities	4.78M	5.25M	5.79M	5.49M	6.10M	6.36M
Stockholders Equity	9.30M	13.46M	28.34M	32.28M	45.12M	4.48M
Cash Flow
Free Cash Flow	-10.02M	-14.58M	-3.72M	-14.97M	1.07M	-4.89M
Operating Cash Flow	-9.95M	-14.09M	-2.76M	-13.70M	2.50M	-4.45M
Investing Cash Flow	-70.00K	-539.00K	-1.16M	28.92M	-31.56M	-519.00K
Financing Cash Flow	3.10M	9.00K	1.11M	1.87M	38.76M	4.46M

Collplant Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 1.51 is below the 20-day moving average (MA) of 1.66, below the 50-day MA of 1.72, and below the 200-day MA of 2.09, indicating a bearish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of 46.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.

Collplant Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PYPD	56 Neutral	$70.11M	-1.46	-390.53%	―	―	61.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$201.38M	-1.29	-21.16%	―	-92.42%	62.37%
PASG	49 Neutral	$32.98M	-0.63	-87.18%	―	―	38.42%
CLGN	48 Neutral	$20.47M	-0.73	-92.74%	―	280.77%	32.82%
DARE	47 Neutral	$25.29M	-3.81	―	―	―	―
NRSN	44 Neutral	$26.67M	-1.49	―	―	―	31.09%

Collplant Holdings Corporate Events

CollPlant Shareholders Approve All Proposals at December 31, 2025 General Meeting

On December 31, 2025, CollPlant Biotechnologies Ltd. held its Annual and Extraordinary General Meeting of Shareholders in which investors approved all four proposals on the agenda, each receiving the requisite majority. The shareholder approvals, which followed the company’s November 26, 2025 notice convening the meeting, clear the way for CollPlant to implement its proposed corporate and governance actions without opposition, supporting continuity in management’s strategic plans and regulatory compliance as a foreign private issuer.

The most recent analyst rating on (CLGN) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

CollPlant Biotechnologies Announces Annual and Extraordinary General Meeting for December 2025

On November 26, 2025, CollPlant Biotechnologies Ltd. announced that it will hold its annual and extraordinary general meeting of shareholders on December 31, 2025, in Tel-Aviv, Israel. The meeting will address several key proposals, including the re-election of board members, re-appointment of auditors, renewal of the compensation policy for directors and officers, and the appointment of CEO Yehiel Tal as interim Chairman of the Board. The outcomes of this meeting could influence the company’s governance and strategic direction, impacting stakeholders and potentially affecting its market position.

The most recent analyst rating on (CLGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

CollPlant Biotechnologies Expands North American Operations and Reports Q3 2025 Results

CollPlant Biotechnologies reported its third-quarter financial results for 2025, highlighting significant advancements and strategic initiatives. The company announced the expansion of its rhCollagen and BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance its market presence. Recent developments include a collaboration with Mayo Clinic to create a humanized bioprinted skin model, and a comparative study showing its bioink, Collink.3D™, outperformed a leading extracellular matrix in tissue formation. Additionally, CollPlant is implementing cost-reduction measures and prioritizing its collaboration with AbbVie and the development of its dermal filler product. The company is also expanding its international distribution network for its tendon-repair product, Vergenix™ STR, into new markets.

The most recent analyst rating on (CLGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.